254 related articles for article (PubMed ID: 34349038)
1. Immune cell infiltration-associated signature in colon cancer and its prognostic implications.
Deng D; Luo X; Zhang S; Xu Z
Aging (Albany NY); 2021 Aug; 13(15):19696-19709. PubMed ID: 34349038
[TBL] [Abstract][Full Text] [Related]
2. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.
Lee SJ; Jun SY; Lee IH; Kang BW; Park SY; Kim HJ; Park JS; Choi GS; Yoon G; Kim JG
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1005-1014. PubMed ID: 29520442
[TBL] [Abstract][Full Text] [Related]
3. Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer.
Guo JN; Chen D; Deng SH; Huang JR; Song JX; Li XY; Cui BB; Liu YL
Cancer Immunol Immunother; 2022 Jun; 71(6):1313-1330. PubMed ID: 34657172
[TBL] [Abstract][Full Text] [Related]
4. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
Yi M; Li A; Zhou L; Chu Q; Luo S; Wu K
Cancer Immunol Immunother; 2021 Jun; 70(6):1705-1719. PubMed ID: 33386920
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
6. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
Front Immunol; 2021; 12():685370. PubMed ID: 34220837
[TBL] [Abstract][Full Text] [Related]
7. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
9. Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer.
Ravensbergen CJ; Polack M; Roelands J; Crobach S; Putter H; Gelderblom H; Tollenaar RAEM; Mesker WE
Cells; 2021 Oct; 10(11):. PubMed ID: 34831157
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy.
Wang Z; Song J; Azami NLB; Sun M
Front Immunol; 2022; 13():802665. PubMed ID: 35572595
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
12. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tumor immune cell infiltration patterns in colon adenocarcinoma based on systematic bioinformatics analysis.
Xu H; Xu Q; Yin L
Cancer Cell Int; 2021 Jul; 21(1):344. PubMed ID: 34217290
[TBL] [Abstract][Full Text] [Related]
14. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
Li H; Li J; Zhang C; Zhang C; Wang H
Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393
[TBL] [Abstract][Full Text] [Related]
15. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
[TBL] [Abstract][Full Text] [Related]
16. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
17. An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.
Chen Y; Li ZY; Zhou GQ; Sun Y
Clin Cancer Res; 2021 Jan; 27(1):330-341. PubMed ID: 33097495
[TBL] [Abstract][Full Text] [Related]
18. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
Front Immunol; 2019; 10():6. PubMed ID: 30761122
[No Abstract] [Full Text] [Related]
19. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer.
Li X; Wen D; Li X; Yao C; Chong W; Chen H
Front Immunol; 2020; 11():1678. PubMed ID: 33013820
[TBL] [Abstract][Full Text] [Related]
20. Uncovering the Immune Cell Infiltration Landscape in Low-Grade Glioma for Aiding Immunotherapy.
Yang Y; Tian Y; Li Q; Jiang R; Zhang J
J Oncol; 2022; 2022():3370727. PubMed ID: 35310911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
